553 related articles for article (PubMed ID: 30736475)
1. The Developing Story of Predictive Biomarkers in Colorectal Cancer.
Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N
J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475
[TBL] [Abstract][Full Text] [Related]
2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer genomics and designing rational trials.
Mondaca S; Yaeger R
Ann Transl Med; 2018 May; 6(9):159. PubMed ID: 29911107
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
To KK; Tong CW; Wu M; Cho WC
World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in colorectal cancer: Current clinical utility and future perspectives.
Vacante M; Borzì AM; Basile F; Biondi A
World J Clin Cases; 2018 Dec; 6(15):869-881. PubMed ID: 30568941
[TBL] [Abstract][Full Text] [Related]
7. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
8. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.
Zarour LR; Anand S; Billingsley KG; Bisson WH; Cercek A; Clarke MF; Coussens LM; Gast CE; Geltzeiler CB; Hansen L; Kelley KA; Lopez CD; Rana SR; Ruhl R; Tsikitis VL; Vaccaro GM; Wong MH; Mayo SC
Cell Mol Gastroenterol Hepatol; 2017 Mar; 3(2):163-173. PubMed ID: 28275683
[TBL] [Abstract][Full Text] [Related]
9. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer.
Sideris M; Papagrigoriadis S
Anticancer Res; 2014 May; 34(5):2061-8. PubMed ID: 24778007
[TBL] [Abstract][Full Text] [Related]
10. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
13. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
14. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
15. The role of tumor markers and biomarkers in colorectal cancer.
Lech G; Slotwinski R; Krasnodebski IW
Neoplasma; 2014; 61(1):1-8. PubMed ID: 24195503
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
Battaglin F; Naseem M; Lenz HJ; Salem ME
Clin Adv Hematol Oncol; 2018 Nov; 16(11):735-745. PubMed ID: 30543589
[TBL] [Abstract][Full Text] [Related]
17. Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.
Crutcher MM; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1317-1326. PubMed ID: 36259230
[TBL] [Abstract][Full Text] [Related]
18. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
19. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.
Mármol I; Sánchez-de-Diego C; Pradilla Dieste A; Cerrada E; Rodriguez Yoldi MJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106826
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.
Fanale D; Castiglia M; Bazan V; Russo A
Adv Exp Med Biol; 2016; 937():207-28. PubMed ID: 27573902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
